Compare GOOS & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOOS | PGEN |
|---|---|---|
| Founded | 1957 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2017 | N/A |
| Metric | GOOS | PGEN |
|---|---|---|
| Price | $12.58 | $4.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $12.80 | $7.67 |
| AVG Volume (30 Days) | 731.1K | ★ 4.0M |
| Earning Date | 02-05-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $984,644,735.00 | $6,309,000.00 |
| Revenue This Year | $8.87 | $342.78 |
| Revenue Next Year | $5.93 | $478.46 |
| P/E Ratio | $64.43 | ★ N/A |
| Revenue Growth | 3.71 | ★ 59.20 |
| 52 Week Low | $6.73 | $1.11 |
| 52 Week High | $15.43 | $5.23 |
| Indicator | GOOS | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 59.57 |
| Support Level | $12.16 | $4.38 |
| Resistance Level | $12.93 | $5.10 |
| Average True Range (ATR) | 0.55 | 0.36 |
| MACD | -0.08 | 0.03 |
| Stochastic Oscillator | 19.31 | 71.37 |
Canada Goose Holdings Inc is a Canada-based company that designs, manufactures, distributes, and retails premium outerwear for men, women, and children. It operates business through three segments namely, Wholesale and Direct to Consumer (DTC), Other. The DTC segment, which is the key revenue driver, comprises sales through country-specific e-commerce platforms and its company-owned retail stores located in luxury shopping locations. The Wholesale segment comprises sales made to a mix of retailers and international distributors, who are partners that have exclusive rights to an entire market, and travel retail locations. Geographically, it has a presence in Canada, the United States, North America, Greater China, Asia, and Europe, the Middle East, and Africa.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.